| Literature DB >> 33802646 |
Ewa Tomaszewska1, Janine Donaldson2, Jakub Kosiński3, Piotr Dobrowolski4, Agnieszka Tomczyk-Warunek3, Monika Hułas-Stasiak4, Krzysztof Lamorski5, Dorota Laskowska-Woźniak6, Siemowit Muszyński6, Rudolf Blicharski3, Tomasz Blicharski3.
Abstract
The aim of this study was to determine the effects of ß-hydroxy-ß-methylbutyrate (HMB) supplementation during pregnancy on postpartum bone tissue quality by assessing changes in trabecular and compact bone as well as in hyaline and epiphyseal cartilage. The experiment was carried out on adult 6-month-old female spiny mice (Acomys cahirinus) divided into three groups: pregnant control (PregCont), pregnant HMB-treated (supplemented with 0.02 g/kg b.w of HMB during the second trimester of pregnancy, PregHMB), and non-pregnant females (NonPreg). Cross-sectional area and cortical index of the femoral mid-shaft, stiffness, and Young modulus were significantly greater in the PregHMB group. Whole-bone mineral density was similar in all groups, and HMB supplementation increased trabecular number. Growth plate cartilage was the thinnest, while the articular cartilage was the thickest in the PregHMB group. HMB supplementation increased the content of proteoglycans in the articular cartilage and the percentage of immature collagen content in metaphyseal trabeculae and compact bone. In summary, dietary HMB supplementation during the second trimester of pregnancy intensifies bone metabolic processes and prevents bone loss during pregnancy.Entities:
Keywords: bone; pregnancy; spiny mouse model; β-hydroxy-β-methylbutyrate
Mesh:
Substances:
Year: 2021 PMID: 33802646 PMCID: PMC8002460 DOI: 10.3390/ijms22063047
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Osteometric, mechanical, and densitometric parameters of femora from pregnant (control and supplemented with β-Hydroxy β-methylbutyrate (HMB)) and non-pregnant female spiny mice.
| Item | PregCont | PregHMB | NonPreg |
|---|---|---|---|
| Weight, g | 0.16 ± 0.02 | 0.15 ± 0.01 | 0.13 ± 0.02 # |
| Length, mm | 20.52 ± 0.24 | 20.31 ± 0.26 | 18.88±0.34 # |
| BMD, g/cm2 | 3.04 ± 0.18 | 2.92 ± 0.30 | 2.95 ± 0.22 |
| Fmax, N | 23.63 ± 5.58 | 24.17 ± 3.25 | 21.48 ± 2.84 |
| Fyield, N | 19.25 ± 1.36 | 18.58 ± 2.77 | 17.51 ± 2.36 |
| S, N/mm | 64.51 ± 5.34 | 81.70 ± 2.45 * | 41.1 5± 5.45 # |
| M, N⋅m | 48.37 ± 1.94 | 48.95 ± 2.29 | 40.56 ± 6.75 # |
| CSMI, mm4 | 0.34 ± 0.06 | 0.32 ± 0.07 | 0.20 ± 0.01 # |
| CSA, mm2 | 1.45 ± 0.09 | 1.56 ± 0.04 * | 1.17 ± 0.05 # |
| MRWT | 0.44 ± 0.05 | 0.54 ± 0.03 * | 0.45 ± 0.05 |
| CI, % | 30.30 ± 0.11 | 34.61 ± 0.41 * | 31.07 ± 2.44 |
Data are mean values ± SD (n = 10 in each group). PregCont—control pregnant females (not receiving HMB); PregHMB—pregnant HMB females (receiving HMB at a dose of 0.02 g/kg b.w. during the middle trimester of pregnancy); NonPreg—non-pregnant females. BMD—bone mineral density; Fmax—ultimate force; Fyield—yield force; S—stiffness, M—bending moment; CSMI—cross-sectional moment of inertia; CSA—cross-sectional area; MRWT—mean relative wall thickness; CI—cortical index. Statistical significance: * p ≤ 0.05 (vs. control group of PregCont), # p ≤ 0.05 (vs. control group of PregCont).
Figure 1Representative micro-CT images of sagittal sections of the right femur distal diaphysis (i), transverse sections of the femur mid-shaft (ii), and transverse sections of the femoral neck (iii) from pregnant (control and supplemented with β-Hydroxy β-methylbutyrate (HMB)) and non-pregnant female spiny mice. PregCont—control pregnant females (not receiving HMB); PregHMB—pregnant HMB females (receiving HMB at a dose of 0.02 g/kg b.w. during the middle trimester of pregnancy); NonPreg—non-pregnant females. Scale bars represent 500 µm.
Material parameters of femora from pregnant (control and supplemented with β-Hydroxy β-methylbutyrate (HMB)) and non-pregnant female spiny mice (Acomys cahirinus).
| Item | PregCont | PregHMB | NonPreg |
|---|---|---|---|
| Young’s modulus, MPa | 1862 ± 204 | 263 9± 112 * | 1937 ± 74 |
| Ultimate strain, % | 5.35 ± 1.25 | 3.54 ± 0.82 * | 6.19 ± 2.15 |
| Elastic stress, MPa | 92.67 ± 4.8 | 89.56 ± 6.89 | 120.12 ± 4.80 # |
| Ultimate stress, MPa | 113 ± 4 | 115 ± 3 | 148 ± 3 # |
Data are mean values ± SD (n = 10 in each group). PregCont—control pregnant females (not receiving HMB); PregHMB—pregnant HMB females (receiving HMB at a dose of 0.02 g/kg b.w. during the middle trimester of pregnancy); NonPreg—non-pregnant females. Statistical significance: * p ≤ 0.05 (vs. control group of PregCont), # p ≤ 0.05 (vs. control group of PregCont).
Osteometric, mechanical, and densitometric parameters of femora from pregnant (control and supplemented with β-Hydroxy β-methylbutyrate (HMB)) and non-pregnant female spiny mice.
| Item | PregCont | PregHMB | NonPreg |
|---|---|---|---|
|
| |||
| BV/TV, % | 30.03 ± 2.74 | 35.28 ± 3.84 * | 27.14 ± 0.81 # |
| Tb.Th, µm | 125.16 ± 17.71 | 56.15 ± 9.01 * | 74.87 ± 9.61 # |
| Tb.Sp, µm | 220 ± 23 | 162 ± 30 * | 286 ± 34 # |
| Tb.N, 1/mm | 4.03 ± 0.27 | 5.59 ± 0.48 * | 3.75 ± 0.39 |
| BS/BV, % | 15.97 ± 3.89 | 11.23 ± 2.40 * | 14.97 ± 1.92 |
|
| |||
| BV/TV, % | 31.41 ± 2.86 | 35.96 ± 2.16 * | 29.41 ± 2.72 |
| Tb.Th, µm | 47.20 ± 8.73 | 45.27 ± 6.66 | 68.03 ± 16.23 # |
| Tb.Sp, µm | 125 ± 19 | 101 ± 13 * | 168 ± 27 # |
| Tb.N, 1/mm | 6.81 ± 1.31 | 8.09 ± 0.91 * | 4.36 ± 0.31 # |
| BS/BV, % | 9.44 ± 2.00 | 7.33 ± 1.09 * | 13.61 ± 3.24 # |
|
| |||
| BV/TV, % | 36.76 ± 2.26 | 36.50 ± 4.45 | 42.13 ± 3.25 # |
| Tb.Th, µm | 104.9 ± 11.5 | 90.5 ± 12.9 * | 112.7 ± 8.93 |
| Tb.Sp, µm | 228 ± 35 | 265 ± 55 | 247 ± 26 |
| Tb.N, 1/mm | 3.47 ± 0.62 | 4.03 ± 0.55 * | 3.82 ± 0.43 # |
| BS/BV, % | 21.34 ± 1.38 | 18.10 ± 2.58 * | 22.17 ± 2.08 |
Data are mean values ± SD (n = 10 in each group). PregCont—control pregnant females (not receiving HMB); PregHMB—pregnant HMB females (receiving HMB at a dose of 0.02 g/kg b.w. during the middle trimester of pregnancy); NonPreg—non-pregnant females. BV/TV—bone volume density; Tb.Th—trabecular thickness; Tb.Sp—trabecular space; Tb.N—trabecular number; BS/BV—specific bone surface. Statistical significance: * p ≤ 0.05 (vs. control group of PregCont), # p ≤ 0.05 (vs. control group of PregCont).
The thickness of the epiphyseal and articular cartilage zones of femora from pregnant (control and supplemented with β-Hydroxy β-methylbutyrate (HMB)) and non-pregnant female spiny mice.
| Item | PregCont | PregHMB | NonPreg |
|---|---|---|---|
|
| |||
| total, µm | 203 ± 31 | 172 ± 13 * | 205 ± 15 |
| I, µm | 24.45 ± 10.92 | 26.33 ± 8.85 | 27.14 ± 8.03 |
| II, µm | 52.08 ± 10.13 | 51.69 ± 11.36 | 68.60 ± 8.96 # |
| III, µm | 46.39 ± 5.37 | 42.46 ± 9.66 | 37.27 ± 8.53 # |
| IV, µm | 48.79 ± 11.21 | 29.72 ± 6.91 * | 58.56 ± 14.59 |
|
| |||
| total, µm | 83.87 ± 5.69 | 92.13 ± 4.92 * | 83.41 ± 5.41 |
| I, µm | 12.07 ± 2.55 | 10.57 ± 3.27 | 6.59 ± 1.31 # |
| II, µm | 28.94 ± 7.59 | 35.18 ± 10.9 | 21.76 ± 7.3 # |
| III, µm | 41.00 ± 2.68 | 48.26 ± 2.88 * | 54.63 ± 2.96 # |
Data are mean values ± SD (n = 10 in each group). PregCont—control pregnant females (not receiving HMB); PregHMB—pregnant HMB females (receiving HMB at a dose of 0.02 g/kg b.w. during the middle trimester of pregnancy); NonPreg—non-pregnant females. Zones of growth plate cartilage: I—resting zone; II—proliferative zone; III—hypertrophic zone; IV—calcified zone. Zones of articular cartilage: I—superficial zone; II—middle (transitional) zone; III—deep zone. Statistical significance: * p ≤ 0.05 (vs. control group of PregCont), # p ≤ 0.05 (vs. control group of PregCont).
Thin collagen content (%) in trabeculae, compact bone and articular cartilage of femora from pregnant (control and supplemented with β-Hydroxy β-methylbutyrate (HMB)) and non-pregnant female spiny mice.
| Item | PregCont | PregHMB | NonPreg |
|---|---|---|---|
| Epiphyseal trabeculae | 0.39 ± 0.13 | 1.08 ± 0.13 * | 0.36 ± 0.14 |
| Metaphyseal trabeculae | 0.87 ± 0.15 | 0.67 ± 0.15 * | 0.27 ± 0.11 # |
| Compact bone | 1.92 ± 0.67 | 2.82 ± 0.09 * | 0.93 ± 0.06 # |
| Articular cartilage | 1.69 ± 1.02 | 1.57 ± 1.05 | 1.63 ± 0.21 |
Data are mean values ± SD (n = 10 in each group). PregCont—control pregnant females (not receiving HMB); PregHMB—pregnant HMB females (receiving HMB at a dose of 0.02 g/kg b.w. during the middle trimester of pregnancy); NonPreg—non-pregnant females. Statistical significance: * p ≤ 0.05 (vs. control group of PregCont), # p ≤ 0.05 (vs. control group of PregCont).
Figure 2Representative images of Safranine O-stained sections of articular cartilage from femora of pregnant (control and supplemented with β-Hydroxy β-methylbutyrate (HMB)) and non-pregnant female spiny mice. PregCont—control pregnant females (not receiving HMB); PregHMB—pregnant HMB females (receiving HMB at a dose of 0.02 g/kg b.w. during the middle trimester of pregnancy); NonPreg—non-pregnant females. Scale bars represent 50 µm.